Anthracyclines, small-molecule inhibitors of hypoxia-inducible factor-1 alpha activation

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 10, 2006, Pages 1999-2003

  Yamazaki, Yohko ^a   Hasebe, Yuki ^b   Egawa, Kiyoshi ^b   Nose, Kiyoshi ^b   Kunimoto, Setsuko ^a   Ikeda, Daishiro ^a  

^a Numazu Bio Medical Research Institute   (Japan)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

Anthracycline; Hypoxia inducible factor 1; Vascular endothelial growth factor

Indexed keywords

ACLARUBICIN; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; CINERUBIN A; DAUNORUBICIN; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUCIFERASE; PROTEIN INHIBITOR; VASCULOTROPIN;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BINDING SITE; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYPOXIA; IC 50; NONHUMAN; PROTEIN INDUCTION; REPORTER GENE; SOLID TUMOR; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ANIMALS; ANTHRACYCLINES; CHO CELLS; CRICETINAE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33749441031     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.1999     Document Type: Article

References (15)

1. Brown J. M., Wilson W. R., Nat. Rev. Cancer, 3, 437-447 (2004).
2. Zhong H., Klafter R. J., Simons J. W., Recent Results Dev. Cancer, 3, 49-68 (2001).
3. Wang G. L., Jiang B. H., Rue E. A., Semenza G. L., Proc. Natl. Acad. Sci. U.S.A., 92, 5510-5514 (1995).
4. Epstein A. C., Gleadle J. M., McNeill L. A., Hewitson K. S., O'Rourke J., Mole D. R., Mukherji M., Metzen E., Wilson M. I., Dhanda A., Tian Y. M., Masson N., Hamilton D. L., Jaakkola P., Barstead R., Hodgkin J., Maxwell P. H., Pugh C. W., Schofield C. J., Ratcliffe P. J., Cell, 107, 43-54 (2001).
5. Bruick R. K., McKnight S. L., Science, 294, 1337-1340 (2001).
6. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J. M., Lane W. S., Kaelin W. G., Jr., Science, 292, 464-468 (2001).
7. Jaakkola P., Mole D. R., Tian Y. M., Wilson M. I., Gielbert J., Gaskell S. J., Kriegsheim A., Hebestreit H. F., Mukherji M., Schofield C. J., Maxwell P. H., Pugh C. W., Ratcliffe P. J., Science, 292, 468-472 (2001).
8. Semenza G. L., Nat. Rev. Cancer, 3, 721-732 (2003).
9. Carmeliet P., Jain R. K., Nature (London), 407, 249-257 (2000).
10. Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K., Cancer Res., 60, 203-212 (2000).
11. Yamazaki Y., Egawa K., Nose K., Kunimoto S., Takeuchi T., Biol. Pharm. Bull., 26, 417-420 (2003).
12. Egawa K., Nishigori H., Kunimoto S., Takeuchi T., Nose K., Biol. Pharm. Bull., 21, 899-904 (1998).
13. Rapisarda A., Uranchimeg B., Sordet O., Pommier Y., Shoemaker R. H., Melillo G., Cancer Res., 64, 1475-1482 (2004).
14. Bridewell D. J., Finlay G. J., Baguley B. C., Oncol. Res., 9, 535-542 (1997).
15. Nitiss J. L., Pourquier P., Pommier Y., Cancer Res., 57, 4564-4569 (1997).